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Angiotensin II receptor regulation in anti-glomerular basement mem-
brane nephritis. The expression of the glomerular receptor for anglo-
tensin II (Ang II-R) was examined longitudinally following the induction
of anti-glomerular basement membrane (GBM) nephritis in the rat. The
specific aim of the project was to determine whether immunologically-
induced glomerular injury led to significant abnormalities of the rela-
tionship between glomerular Ang II-R and its circulating ligand, Ang II.
Scatchard analysis was used to measure Ang H-R on purified glomeruli
at selected time intervals over two months following a single dose of
sheep anti-rat GBM antibody. Corresponding values for plasma Ang II
were determined. Receptor density fell to approximately 50% by 16
hours following the injection of antibody (control 96.4 9.3 x 106:
nephritic 52.6 5.6 x 106 receptors/glomerulus; P < 0.001) and there
was a corresponding threefold increase in plasma Ang H (control 21.0
2.5; nephritic 66.6 20.6 pg/mI; P < 0.01). However, this reduction in
receptor binding could not be explained by the rise in plasma Ang II
concentration, as effective blockade of the RAS by enalapril did not
alter receptor expression (56.1 4.6 x 106 receptors/glomerulus).
Subsequently, a rise in receptor density and a corresponding fall in
plasma Ang II were observed: three days after antibody administration,
receptor concentration had increased significantly above control values
(150.5 11.9 x 106) while plasma Ang II was undetectable (that is, <5
pg/mi). Ang IL-R remained elevated for the next two weeks but returned
to normal four to eight weeks after the administration of nephrotoxic
antibody. Circulating Ang II levels remained low for the duration of the
study. Administration of normal sheep globulin did not alter receptor
density (88.7 10.0 x 106), These studies demonstrate significant
dissociation of plasma Ang II and its glomerular receptor during the
course of anti-GBM nephritis in the rat. This indicates that Ang H-R is
no longer under the control of components of the circulating RAS and
may show an inappropriate response to variations in the level of
circulating ligand. Such an abnormality could have an unfavorable
influence on glomerular hemodynamics in the long-term.
The immunopathogenesis of glomerular injury in both man
and experimental animals has been extensively investigated [1].
However, while there is sound evidence for immune-mediated
injury in the initial phase of glomerulonephritis (GN) [2], the
factors that determine whether such lesions progress to renal
failure remain unresolved; progression may occur irrespective
of apparent cessation of active immunological events. This
decline in renal function coincides with reduction in glomerular
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blood flow, glomerular hyperfiltration and ultimate glomerular
sclerosis [3].
The potent vasoconstrictor angiotensin II (Ang II) is an
important factor in the control of glomerular hemodynamics
and interacts with specific, high-affinity receptors that are
located in the glomerular mesangium and efferent arteriole
[4—6]. Several studies have documented changes in the relation-
ship between the circulating renin-angiotensin system (RAS)
and Ang II receptors during the course of experimental diabetes
mellitus and acute renal failure [7—10]. It has also been shown
that inhibition of Ang II production by the administration of
angiotensin converting enzyme (ACE) inhibitors results in
significant reduction in proteinuria in patients with glomerular
disease (including diabetic glomeruloscierosis) and in some
experimental models of GN [11—13].
It is possible that immunological glomerular injury causes
long-term structural and/or functional modification of receptor
sites involved in the regulation of glomerular blood flow. This,
in turn might contribute to the progress of renal failure after
immune-mediated processes are no longer demonstrable. To
investigate this hypothesis we have studied the regulation of
glomerular Ang II receptor expression during the course of
anti-glomerular basement membrane (GBM)-mediated GN in
the rat. Significant changes in glomerular blood flow have been
documented in this model [3]. We measured the affinity and
density of Ang II receptors in isolated glomeruli for up to two
months following the induction of glomerular injury by a single
dose of purified heterologous nephrotoxic immunoglobulin (Ig).
Methods
Experimental animals
Adult male Sprague-Dawley rats (300 to 450 g) were used in
all experimental procedures and were maintained on normal rat
chow with ad libitum access to tap water except where other-
wise stated.
Group 1: Modulation of receptor density by sodium intake. A
preliminary study was performed to confirm the responsiveness
of glomerular Ang II receptors to variations in plasma Ang II
concentration induced by changes in sodium intake. One group
of animals was fed normal rat chow (1% Na, wet/wt) and
allowed free access to tap water. A second group was main-
tained on a high sodium diet (4% Na, wet/wt) and given 0.9%
NaCl to drink. A low sodium diet (<0.4% Na, wet/wt) was
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given to a third group of animals who were given access only to
deionised water; they also received daily injections of
frusemide (1 mg/kg i.p.) for five days prior to binding studies.
Animals were maintained on these diets for a minimum of three
weeks. The diets were prepared according to the method of
Harrap and Doyle [14] with the addition of appropriate quanti-
ties of sodium where required. Urinary sodium and protein
excretion were measured for 24 hours prior to Ang II receptor
characterisation.
Group 2: Nephrotoxic serum nephritis. Rat GBM was puri-
fied from isolated glomerular and anti-rat GBM antibodies
raised in a sheep by repeated immunization with GBM in
complete and incomplete Freund's adjuvant [15]. Nephrotoxic
serum was decomplemented by heating at 56°C for 30 minutes
and absorbed against packed rat red blood cells to remove
cross-reactive antibodies. Nephrotoxic Ig was purified from
whole sheep serum by 45% ammonium sulphate precipitation
and microfiltered (Millipore) prior to storage at —20°C. Anti-
GBM nephritis was induced by the i.v. administration of a high
dose (100 pg/g body wt) of purified sheep anti-rat GBM Ig (via
the tail vein under light halothane anaesthesia). Receptor stud-
ies were performed at 16 hours and 3, 7, 10, 14, 28, 42 and 56
days following the injection of nephrotoxic 1g. Animals to be
studied 28, 42 and 56 days following the induction of nephritis
also received a subcutaneous pre-immunization dose of sheep
Ig (4 mg) in complete Freund's adjuvant 48 hours prior to the
i.v. dose in order to maintain disease activity. During the course
of the study animals underwent periodic measurement of 24
hour UaV, urea, creatinine and protein excretion. Animals
who received nephrotoxic serum were designated as Group A.
In control experiments, glomerular Ang II receptor charac-
teristics were studied 16 and 72 hours after the i.v. administra-
tion of a comparable dose of Ig isolated from normal sheep
serum in a similar fashion to the nephrotoxic Ig (Group B).
Another group of rats (Group C) were studied after receiving 2
mg heat aggregated (63°C) gamma globulin (in I ml sterile
physiological saline) as a non-specific immune activator. It had
been determined that this dose of aggregates caused significant
complement activation, as judged by a 50% decrease and
subsequent threefold increase in serum hemolytic activity. The
angiotensin converting enzyme (ACE) inhibitor enalapril male-
ate was administered in the drinking water (300 mg/liter) to a
fourth group (Group D) for five days before and 16 hours after
the administration of nephrotoxic antibody. Normal animals,
maintained on enalapril alone were also studied.
The systolic blood pressure of conscious rats from each
experimental group was measured using a tail cuff pneumatic
sensor attached to a pulse transducer (Narco Bio-systems) and
a Neotrace chart recorder. Urinary protein content was deter-
mined by a spectrophotometric method using Coomassie Blue.
At selected times rats were killed by cervical dislocation and
the kidneys removed rapidly for histological and receptor
analysis. Arterial blood samples were also obtained for the
determination of plasma Ang II.
Glomerular angiotensin II receptor assay
Radioligand production. The angiotensin II antagonist
(Sar1 ,11e8)Ang II (Peninsula) was radio-iodinated with Na-I'25
(Amersham Corp., Arlington Heights, Illinois, USA) by the
modified lactoperoxidase method [16] and purified by passage
through a 10 ml G-lO Sephadex column (Pharmacia, Uppsala,
Sweden) pre-equilibrated in PBS with Medium-199 (CSL).
Specific activity (—2000 sCi/sg) was calculated by the method
of Hunter and Greenwood [171 and by radioimmunoassay of the
labelled compound using (Sar' ,Ile8)Ang II as the standard. 1125
(Sar',Ile8)Ang II was aliquoted, stored at —80°C and used
within four weeks of production.
Preparation of isolated glomeruli. Glomeruli were isolated by
modification of the method of Fong and Drummond [18].
Briefly, kidneys were removed and chilled immediately to 4°C
in phosphate buffered saline (PBS, Oxoid), pH 7.5. The cortex
was minced and pushed gently through a 250 jsm seive with
copious washing with ice-cold PBS. The filtrate was passed
through a 150 sm seive onto a 63 jun seive and the retained
material centrifuged twice in fresh cold PBS (10 ml) at 500 rpm
for three minutes. Glomeruli were decapsulated by passage
through a fine gauge needle and capsules removed by centrifu-
gation. Microscopic examination of the final suspension re-
vealed the glomerular preparations to be more than 95% pure.
Binding conditions. The binding of Ang II to glomeruli was
assessed as follows: approximately 2000 glomeruli per tube
were incubated at 22°C for 60 minutes in a 10 mM NaPO4 buffer
containing 5 mM EDTA, 1 mi phenylmethylsuiphonyifluoride
(PMSF), 0.02% sodium azide, 0.2% bovine serum albumin and
1 mg/mi bacitracin in the presence of eight concentrations of
V25 (Sar1,11e8)Ang II (range: 100 n to 0.1 nM). Bound and free
ligand were separated by filtration on GF/B glass fiber filters
(Whatman) by a Brandell cell harvester. 1125 was counted on a
NE-1600 gamma counter with 77% efficiency. Maximal binding
accounted for 15 to 25% of the total added counts, while
background binding of the ligand to the filters accounted for less
than 0.1%.
Receptor binding analysis. Binding parameters, receptor
number (Bmax) and binding affinity (Kd) were calculated with
the iterative analysis program, LIGAND [19]. Glomerular con-
centration was determined on duplicate 20 p1 aliquots of gb-
merular suspension. Mathematical adjustments for non-specific
binding and slight variations in glomerular concentration be-
tween preparations were incorporated into the LIGAND anal-
ysis [20]. Initial studies validated the use of computerized
LIGAND analysis to correct for non-specific binding. Theoret-
ically-generated specific binding curves were comparable to
those obtained when non-specific binding was quantitated in the
presence of 100-fold excess cold (Sar1,Ile8)Ang II. The number
of binding sites per glomerulus was determined by the following
formula:
receptor number — Ang II bound Avagadro's number
(x 106/glomerulus — (fmollglomerulus) X (molecules/mole)
This assumes saturation of receptor sites with one molecule
of Ang II per receptor.
Plasma Ang II determination
Plasma Ang II was measured by modification of methods
previously described [21]. At the time of analysis, 5 ml arterial
blood was collected into chilled test tubes containing 0.25 ml 0.3
M EDTA and 0.15 ml 0.2 M 2,3-dimercapto-1-propanol. Plasma,
made up to a volume of 10 ml with 0.9% NaCI, was loaded onto
a primed C-18 SEPAK (Waters) and Ang II extracted with 2 ml
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Bound (Sar1 lie8) Ang II
x 106 receptorslg/omerulus
Fig. 1. Scarchard plots of (Sar'I!e8)Ang II binding to glomeruli iso-
lated from norma! (0) or experimental rats (•) 16 hours after admin-
istration of nephrotoxic serum. Hormone receptor affinity was not
affected, as demonstrated by the parallel lines. The dissociation con-
stant (Kd) was 4.6 1.6 x i0 54 in the normal group and 3.8 0.9 >(
M in the nephritic group.
acetonitrile : water: acetic acid (75:24:4). The supernatant was
blown down to dryness under nitrogen at 37°C. Dry extracts
were reconstituted in 0.2 ml barbitone buffer and assayed for
Ang II content using commercial 1125-Ang II (NEN) and specific
antibody. The Ang II antibody cross reacted to a small extent
with angiotensin I (<0.01%). Assay sensitivity was 0.1 pg Ang
IIIml.
Statistical analysis
Normally distributed data were expressed as the mean
SEM, while the median and range were specified for non-
parametric data. For analysis, data that fell outside the limits of
the assay employed (that is, urinary Na <10 mmol/liter and
plasma Ang II < 5 pg/mI) were given arbitrary values (9
mmollliter and 4.5 pg/mI, respectively) and non-parametric
analysis used to test significance. The paired and unpaired
Student's t-tests were used to determine the significance of
differences where data conformed to a normal distribution. The
Mann-Whitney U test was used for analysis of non-parametric
data.
Results
Radioligand Scatchard analysis identified a single class of
high affinity receptors for Ang II in glomeruli isolated from
normal and experimental animals (Fig. 1). Receptor density for
untreated control animals was 96.4 9.3 x 106 receptors!
glomerulus (N = 10), with binding dissociation constants (Kd)
of 4.6 1.6 x l0— M. Plasma Ang II concentration in these
animals was 21.0 2.5 pg!ml.
A significant increase in plasma Ang II was seen in rats
maintained on a low sodium diet (262 30 pg/mI, N = 6, P <
0.001) with a corresponding fall in receptor expression (47.3
4.8 x 106 receptors/glomerulus, N =6, P < 0.001). Conversely,
plasma Ang II was significantly depressed (<5.0 pg!ml) in
animals on a high sodium diet and this was accompanied by an
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increase in glomerular Ang II receptor density (144.1 13.8 x
106 receptors!glomerulus, N = 7, P < 0.02). Binding affinity was
unaffected by either sodium repletion or depletion (K4 =5.1
0.47, and 4.7 0.38 x iO M, respectively).
Rats developed significant proteinuria within 24 hours of the
administration of nephrotoxic 1g. (Fig. 2). This was associated
with a decreased urinary sodium concentration (that is, <10
mmollliter) in most animals and oliguria which persisted
throughout the study. Proteinuria also continued throughout the
course of the disease. Urinary Na concentration returned to
normal 10 to 14 days after the injection of antibody.
Immunofluorescence examination of renal tissue showed
grade 4 linear deposition of IgG along the GBM of all animals
(for the duration of the study). Light microscopy demonstrated
thickening of the basement membrane, mesangial hypercellu-
larity, distention of Bowman's space and mild infiltration of
inflammatory cells.
Glomeruli isolated from rats following the administration of
anti-GBM antibodies also displayed a single class of Ang II
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Fig. 2. Variations in clinical and laboratory parameters following
induction of nephrotoxic nephriris, Each point represents the mean
SEM or median data derived from at least six animals. < 0.05; <
0.01. § indicates non-parametrically distributed data.
'a
a'
E
x
0
0.
a'0
a,
0(
4
0
0'
C4
(a
E
(a0
receptors with a binding affinity similar to normal controls.
Figure 3 shows the variation in giomerular Ang II receptors
during the time course of nephrotoxic nephritis. Corresponding
plasma Ang II concentrations are also shown. There was a
significant reduction in Ang II receptor number 16 hours after
the initiation of GN compared to controls (52.6 5.6 x 106
receptors/giomerulus, N 8, P < 0.001), and this was accom-
panied by a threefold increase in plasma Ang 11(66.6 20.6
pg/mi, P < 0.01). Subsequently, a rise in receptor density and a
fall in plasma Ang II was observed. Three days after antibody
administration, receptor concentration had increased signifi-
cantly above that of controls (150.5 11.9 x 106 receptors!
glomerulus, N = 6, P < 0.01), while plasma Ang II was
undetectable (<5.0 pg!ml) in all animals. Ang II receptor
density remained elevated for the next 14 days before returning
to normal four to eight weeks after the administration of
nephrotoxic Ig; plasma Ang II concentration remained low
throughout this period (<5.0 pg/mi).
A slight transient fall in systolic blood pressure was noted in
all animals during general anaesthesia for the administration of
Ig and aggregates. However, blood pressure returned to normal
within 15 to 20 minutes of cessation of anaesthetic and remained
normal for the rest of the study. The mean systolic blood
pressure of animals in the control groups (B and C) did not vary
significantly from normal, while animals that received enalapril
0)
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Fig. 4. Percentage changes in plasma Ang II concentration and gb-
merular receptor density 16 hours following administration of nephro-
toxic and non-nephrotoxic Ig and aggregated gammagbobulin. Glomer-
ular Ang II receptor number remained unaltered after the injection of
normal sheep Ig, whereas non-specific immune activation by aggregates
caused a slight but significant fall in receptor density. In both cases,
plasma Ang H was significantly depressed.
were slightly hypotensive (normal: 124 2 mm Hg, N = 11;
enaiaprii-treated: 114 5 mm Hg, N 12; P < 0.01).
Other studies tested the specificity of our findings for neph-
rotoxic heterologous antibody. Sixteen and 72 hours after the
injection of a comparable dose of non-nephrotoxic heterologous
Ig, glomerular Ang II receptor density remained unchanged
when compared to controls (88.7 10 x 106 receptors/giomer-
ulus, N = 5, and 89.2 6.0 x 106 receptors/glomerulus, N = 5,
respectively). During this time UNa concentration, urine output
and protein excretion remained unaltered and histological ex-
amination showed no significant glomerular abnormalities.
However, plasma Ang II concentration in these animals was
slightly decreased at both 16 and 72 hours (10.3 1.8 pg/mI, and
9.5 0.5 pg!ml, respectively; Fig. 4). Binding parameters were
also quantitated at 16 and 72 hours following non-specific
immune activation by aggregated gamma globulin. Binding
affinity was unaltered by this regimen and it was found that Ang
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Fig. 3. Changes observed in gbomerular Ang II receptor density and
plasma Ang II during the course of nephrotoxic nephritis. Data are the
mean SEM of at least five experiments. *D < 0.05. Shaded areas
indicate normal ranges determined from 10 control animals.
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Fig. 5. Effect of RAS blockade with enalapril on the density of Ang II
receptors in normal rats and following the administration of nephro-
toxic sheep globulin. Glomeruli isolated from normal rats maintained on
enalapril () bound significantly more Ang II than untreated controls
(Lu, P < 0.01. However, receptor density in experimental animals was
unaltered by enalapril therapy despite plasma Ang II being undetectable
in these animals. There were significant differences (*P < 0.05) between
enalapril-treated animals and their untreated counterparts.
II receptor density was slightly (but significantly) reduced (69.7
7.2 x 106 receptors/glomerulus, N = 10, P < 0.05 and 70.9
4.9 x 106 receptors/glomerulus, N =9, P < 0.05, respectively).
Protein excretion was unaffected by the administration of these
immune aggregates (pre: 6.93 0.5 mg124 hr. N = 10; 16 hr
post: 7.87 1.0, N = 10; 72 hr post: 5.02 0.81, N = 9).
At the time of receptor analysis, plasma Ang II could not be
detected in animals in Group D following treatment with
enalapril maleate. However, no significant difference in recep-
tor density was detected between these treated animals and
their untreated counterparts (Fig. 5). In contrast, Ang II binding
in normal animals maintained on enalapril was significantly
increased (170 16 x 106 receptors/glomerulus, N = 5, P <
0.01). While a significant increase in protein excretion was
observed in animals in the 16 hours following the injection of
nephrotoxic Ig, no such increase was seen in animals treated
with enalapril prior to immunization (Fig. 6). Urine volume and
creatinine excretion were comparable for the treated and un-
treated groups. Furthermore, only animals who were not on
ACE inhibitory therapy prior to receiving nephrotoxic Ig de-
veloped pronounced hematuria.
Discussion
We observed significant changes in the relationship between
glomerular Ang II-R and plasma Ang II during the course of
anti-GBM nephritis in the rat. An apparently physiological
(inverse) relationship was observed for approximately 72 hours
following the injection of nephrotoxic antibody, but this was not
observed during the autologous phase of the disease (Fig. 3).
Preliminary experiments showed that changes in plasma Ang II
and Ang II-R were responsive to variations in dietary sodium
intake, thus confirming observations by previous workers [22,
23]; these data demonstrated the sensitivity of our assay con-
ditions to changes in these two parameters.
Other groups have demonstrated changes in Ang II-R during
the heterologous phase of anti-GBM nephritis. Sraer et al [15]
showed that glomeruli, pre-exposed to anti-GBM antibody both
in vivo and in vitro, bound significantly less Ang II than
controls. Schreiner and Moore [24] confirmed this finding and
further showed that there was no change in the number of
receptor-bearing cells, thus indicating that receptor modulation
occurred on a per cell basis. These latter studies did not report
corresponding values for plasma Ang II, and therefore precise
interpretation of the receptor abnormalities was not possible.
We examined the specificity of these early receptor changes by
testing the effect of normal sheep Ig on receptor characteristics.
A comparable dose of non-nephrotoxic sheep globulin caused
no change in receptor density at 16 and 72 hours. However,
non-specific immune activation (that is, with aggregated gamma
globulin) caused a slight decrease in both Ang II-R and plasma
Ang II (Fig. 4). Such changes could reflect subtle subcellular
damage and subsequent variation in membrane receptor expres-
sion, although no evidence of gross injury was observed on light
microscopy. Alternatively, the injection of aggregates could
generate immune reactants with the capacity to influence Ang II
receptor expression (Schreiner and co-workers have suggested
that complement activation may modify glomerular Ang II-R
[24]). It is also possible that the slight reduction in plasma Ang
II that occurred with these control experiments resulted from a
physiological response to volume expansion, that is, through
the injection of carrier solution (1 ml).
Despite the apparently normal relationship between plasma
Ang II and Ang II-R during the heterologous phase of anti-GBM
nephritis, further experiments show that receptor expression
was independent of the circulating RAS. Specifically, the effec-
tive inhibition of plasma Ang II formation (by ACE inhibition)
did not prevent reduction in Ang II-R (Fig. 5). This implies
dissociation of receptor number and plasma Ang II, and this
abnormality was sustained throughout the autologous phase
(until 60 days; Fig. 3). However, it is not possible to explain the
persistently low plasma Ang II in terms of structural or func-
tional glomerular damage alone. While such an explanation
might account for variations in Ang II-R density, the basis for
the low plasma Ang II is uncertain. This abnormality does not
occur in most human forms of glomerular disease, and it is
possible that cross reactivity between nephrotoxic globulin and
pulmonary antigens contributed to the impaired conversion of
plasma Ang I to Ang II. Irrespective of the basis of this
abnormality, its persistence throughout the course of a single-
dose model of glomerular disease emphasises the prolonged
effect of immunological injury on the components of the recep-
tor/ligand complex.
Of fundamental importance to our study are the possible
long-term consequences of this disordered receptor/ligand rela-
tionship. Indeed, the intrarenal hemodynamic changes of acute
anti-GBM nephritis have been studied in detail [25, 26]. Firstly,
it has been shown that the administration of specific antibody
causes significant decrease in glomerular plasma flow (Qa) and
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single nephron GFR within 60 minutes, principally through
alteration in the ultrafiltration coefficient (LpA). Secondly,
there is an increase in renal vascular resistance and this is
usually accompanied by significant complement fixation (and
activation) with infiltration by inflammatory cells. Pertubation
of complement, either by depletion or infusion of biologically
active fragments (such as C5a), cause significant changes in
intraglomerular hemodynamics [27,28]. Boyce and Holdsworth
[26] have demonstrated similar hemodynamic changes in the
isolated perfused kidney following the administration of anti-
GBM antibody. These experiments emphasised that glomerular
injury can occur independently of inflammatory cell infiltration
or complement deposition, at least in the experimental situa-
tion. This group also demonstrated increased renal renin activ-
ity in the same model after the injection of nephrotoxic antibody
which suggests that antibody deposition contributed to activa-
tion of the intrarenal RAS. (We observed a corresponding
elevation of plasma Ang II concentration at this time in the
disease). These findings suggest that fixation of anti-GBM
antibody caused initial intrarenal vasodilation associated with
subsequent activation of the RAS. Thus, increased plasma Ang
II would explain the reduction in GFR [25, 26] and the increase
in sodium and water reabsorption. Our data have defined a
failure of the up-regulation in Ang II receptor site number which
would be expected in the presence of sustained depression of
circulating Ang II concentration in the autologous phase of
nephritis. We have not established whether or not this is a total
dislocation of the agonist-receptor site nexus which would
result in a corresponding lack of down-regulation in the face of
normal or elevated circulating Ang II (such as has been ob-
served in human GN). Such a phenomenon would result in
accentuated hemodynamic effects of Ang II and could be
confirmed by assessing glomerular Ang II binding during induc-
tion of normal or high plasma Ang II by exogenous infusion.
Treatment with enalapril caused significant reduction in pro-
teinuria in the early phase of anti-GBM nephritis (Fig. 6).
Previous investigators have shown that treatment with ACE
inhibitors results in a significant reduction in proteinuria in
patients with diabetic nephropathy and primary glomerular
disease and in some experimental models of nephritis [11—13].
Increased glomerular filtration pressure, that results from Ang
lI-induced efferent arteriolar constriction, is a factor contribut-
ing to proteinuria [29, 30]. Micropuncture studies suggest that
converting enzyme inhibitors reduce efferent arteriolar resis-
tance, lower glomerular capillary hydraulic pressure and thus
prevent glomerular capillary hypertension. Normalization of
these parameters by blockade of the RAS could be the mecha-
nism by which ACE inhibitor therapy reduces proteinuria in
this model. While the rats that received enalapril therapy had a
lower blood pressure than control animals, this difference was
minor and would not be expected to alter significantly glomer-
ular perfusion or protein excretion.
In conclusion, we have demonstrated a significant decrease in
glomerular Ang II receptor density during the acute phase of
anti-GBM nephritis. Similar changes in receptor density could
be initiated, to a lesser extent, by generalized non-specific
immune activation. Subsequently, Ang II receptor expression
increased significantly before returning to normal levels four to
eight weeks after the administration of nephrotoxic 1g. These
changes did not appear to be in response to variations in plasma
Ang II concentration (either in the short- or long-term) and
pharmacological pertubation of the RAS did not alter the
expression of Ang II receptors. However, the possible regula-
tory role of Ang II, generated within glomeruli and artenolar
walls, requires further investigation.
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